During the recent session, Nuvation Bio Inc (NYSE:NUVB)’s traded shares were 1.1 million, with the beta value of the company hitting 1.46. At the last check today, the stock’s price was $1.86, reflecting an intraday loss of -1.84% or -$0.03. The 52-week high for the NUVB share is $4.16, that puts it down -123.66 from that peak though still a striking 10.22% gain since the share price plummeted to a 52-week low of $1.67. The company’s market capitalization is $626.25M, and the average trade volume was 2.44 million shares over the past three months.
Nuvation Bio Inc (NUVB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. NUVB has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.12.
Nuvation Bio Inc (NYSE:NUVB) trade information
Nuvation Bio Inc (NUVB) registered a -1.84% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.84% in intraday trading to $1.86, hitting a weekly high. The stock’s 5-day price performance is -5.83%, and it has moved by -24.28% in 30 days. Based on these gigs, the overall price performance for the year is -14.90%.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 73.43% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, NUVB is trading at a discount of -276.34% off the target high and -276.34% off the low.
Nuvation Bio Inc (NUVB) estimates and forecasts
In the rating firms’ projections, revenue will increase 55.50% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 625k as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 625k by the end of current fiscal year.
While earnings are projected to return 74.09% in 2025, the next five years will return 35.86% per annum.
NUVB Dividends
Nuvation Bio Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
The next largest institutional holding, with 19.21 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 7.8491% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $56.09 million.
Also, the Mutual Funds coming in first place with the largest holdings of Nuvation Bio Inc (NUVB) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. Data provided on Dec 31, 2024 indicates that Fidelity Growth Company Fund owns about 13.83 shares. This amounts to just over 4.11 percent of the company’s overall shares, with a $25.31 million market value. The same data shows that the other fund manager holds slightly less at 6.13, or about 1.82% of the stock, which is worth about $11.21 million.
